Charcot neuro-osteoarthropathy (CN)—often called the Charcot foot—is one of the most serious and frequently missed complications of diabetes. It is a progressive condition in which the bones and joints of an insensate foot fragment, dislocate, and collapse, sometimes over a matter of weeks. Because the earliest stage can look like a simple sprain or infection, recognizing it quickly is critical: a delay in diagnosis is one of the strongest predictors of permanent deformity, ulceration, and eventually amputation. In 2023, the International Working Group on the Diabetic Foot (IWGDF) published its first dedicated evidence-based guideline on active CN, underscoring how central early recognition has become to limb preservation.
Why the Charcot Foot Develops
CN occurs almost exclusively in people who have lost protective sensation from diabetic peripheral neuropathy. The prevailing model holds that an initial insult—which may be minor or even unnoticed—triggers an uncontrolled local inflammatory response. Inflammatory cytokines drive increased activity of the RANKL/RANK/OPG signalling pathway, tipping the balance toward osteoclast-mediated bone resorption. The result is weakened, brittle bone that continues to bear weight because the patient feels no pain. Advanced glycation end-products, endothelial dysfunction, altered blood flow, and mechanical loading are all thought to contribute to this destructive cycle, as reviewed by Pitocco and colleagues. Without protective pain to prompt rest, ordinary walking accelerates the fractures and joint dislocations that define the disease.
Recognizing the Acute Phase
The acute Charcot foot classically presents as a warm, red, and swollen foot or ankle in a person with neuropathy. Clinicians are advised to maintain a high index of suspicion: any neuropathic patient with unexplained unilateral erythema, edema, and warmth should be considered to have active CN until proven otherwise. A useful bedside clue is a skin-temperature difference of several degrees between the affected and unaffected foot. Because early plain radiographs can appear normal, magnetic resonance imaging is often required to detect the bone marrow edema and microfractures of the earliest stage. Prompt recognition matters enormously, since the window in which immobilization can prevent collapse is narrow.
Charcot Versus Infection
One of the most difficult distinctions in diabetic foot care is separating CN from osteomyelitis, because both can produce a warm, swollen foot with radiographic bone changes. Misclassification runs in both directions and carries real consequences: mistaking Charcot for infection can lead to unnecessary antibiotics or surgery, while missing a true infection can be limb-threatening. As a case series by Pham and colleagues illustrates, patients with fragmentation on imaging were correctly managed as Charcot with immobilization and offloading alone, resolving without antibiotics or operative intervention. The presence of an open ulcer overlying the bone, laboratory markers, and advanced imaging all help guide this judgment, but clinical context remains essential.
Management: Offloading Is the Foundation
The cornerstone of treatment for the active Charcot foot is immobilization and offloading of the affected limb. The IWGDF guideline and conservative-management literature both emphasize that a total contact cast or equivalent non-removable device should be applied as soon as the diagnosis is suspected, with the patient kept non-weight-bearing until the involved bones and joints have consolidated. This period frequently lasts several months, and casting is continued until skin temperatures normalize and imaging confirms coalescence. Schweitzer and Rockhill stress that patient education and expectation management are decisive: adherence to prolonged offloading is difficult, yet it is precisely what prevents the deformity, ulceration, and amputation that follow untreated disease. Pharmacologic agents such as bisphosphonates have been studied but are not established as standard therapy. Surgical reconstruction is generally reserved for unstable deformities, recurrent ulceration, or feet that cannot be accommodated in footwear, and is undertaken by teams experienced in Charcot correction.
A Growing Clinical Burden
Epidemiologic data suggest the problem is not receding. A retrospective analysis of Texas hospital discharge records by Cole and Jupiter found that age-standardized rates of diabetic CN rose across most years between 2006 and 2016, and that both major and minor amputations among patients with CN increased over the same period. The authors interpret these trends as a call for more standardized approaches to diagnosis and management, echoing the rationale behind the IWGDF’s decision to issue a formal guideline.
Key Takeaways
Charcot neuro-osteoarthropathy is a limb-threatening emergency that hides behind unremarkable early symptoms. In any patient with diabetic neuropathy, a unilateral warm, swollen foot should prompt consideration of active CN and urgent offloading rather than watchful waiting. Distinguishing Charcot from osteomyelitis is essential to avoid both overtreatment and dangerous undertreatment. Prolonged immobilization in a total contact cast until the bones consolidate remains the foundation of care, and sustained patient education is central to a good outcome. With rising incidence and amputation rates, early recognition and consistent, guideline-based management offer the best opportunity to preserve the limb.
References
Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2023;40(3):e3646.
Schweitzer M, Rockhill S. Conservative Management of Charcot Neuroarthropathy. Clinics in Podiatric Medicine and Surgery. 2022;39(4):585–594.
Pitocco D, Scavone G, Di Leo M, et al. Charcot Neuroarthropathy: From the Laboratory to the Bedside. Current Diabetes Reviews. 2020;16(1):62–72.
Pham HT, Sanders E, Mendeszoon ER, Tseng W. Charcot Neuroarthropathy Versus Osteomyelitis: A Case Series. Wounds. 2023;35(6):E203–E208.
Cole KA, Jupiter DC. Charcot Neuroarthropathy in Diabetic Patients in Texas. Primary Care Diabetes. 2024;18(5):533–538.
Comments
